Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Cloughesy

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed GlioblastomaMartin J B Taphoorn, Roger Henriksson, Andrew Bottomley, et al.
Journal of Neuro-Oncology|September 28, 2010
Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 casesOrestes E Solis, Rupal I Mehta, Albert Lai, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysisPercy Lee, Wietse Eppinga, Frank Lagerwaard, et al.
Cancer Research|November 26, 2009
Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical modelChristina H Wang, Jason K Rockhill, Maciej Mrugala, et al.
Investigational New Drugs|August 5, 2004
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugsSusan M Chang, John Kuhn, Patrick Wen, et al.
The New England Journal of Medicine|February 21, 2014
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastomaOlivier L Chinot, Wolfgang Wick, Warren Mason, et al.
Neuro-Oncology|March 28, 2002
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium StudyH Ian Robins, Susan M Chang, Michael D Prados, et al.
Neuro-Oncology|March 6, 2024
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse gliomaIsabel Arrillaga-Romany, Andrew Lassman, Susan L McGovern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2003
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium studyKurt A Jaeckle, Kenneth R Hess, W K Alfred Yung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2023
Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaHenry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed GlioblastomaMartin J B Taphoorn, Roger Henriksson, Andrew Bottomley, et al.
Journal of Neuro-Oncology|September 28, 2010
Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 casesOrestes E Solis, Rupal I Mehta, Albert Lai, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysisPercy Lee, Wietse Eppinga, Frank Lagerwaard, et al.
Cancer Research|November 26, 2009
Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical modelChristina H Wang, Jason K Rockhill, Maciej Mrugala, et al.
Investigational New Drugs|August 5, 2004
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugsSusan M Chang, John Kuhn, Patrick Wen, et al.
The New England Journal of Medicine|February 21, 2014
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastomaOlivier L Chinot, Wolfgang Wick, Warren Mason, et al.
Neuro-Oncology|March 28, 2002
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium StudyH Ian Robins, Susan M Chang, Michael D Prados, et al.
Neuro-Oncology|March 6, 2024
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse gliomaIsabel Arrillaga-Romany, Andrew Lassman, Susan L McGovern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2003
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium studyKurt A Jaeckle, Kenneth R Hess, W K Alfred Yung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2023
Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaHenry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Pageof 10